⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 1996JNCI Journal of the National Cancer Institute

Defining Clinically Significant Prostate Cancer: Pathologic Criteria Versus Outcomes Data

Peter C. Albertsen

View at Publisher

Ask AI

Bookmark

Share

Abstract

Peter C. Albertsen; Defining Clinically Significant Prostate Cancer: Pathologic Criteria Versus Outcomes Data, JNCI: Journal of the National Cancer Institute, V

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peter C. Albertsen (1996) studied this question.

synapsesocial.com/papers/6a6d3f10ce524a4339c2b44e https://doi.org/10.1093/jnci/88.17.1177

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Employment after curative breast cancer treatment: the breast cancer and the workforce cohort studyJNCI Journal of the National Cancer Institute · Fri,
2A clinical model incorporating early lymphocyte dynamics in HER2-positive breast cancerJNCI Journal of the National Cancer Institute · Fri,
3Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysisJNCI Journal of the National Cancer Institute · Fri,
4Foundation models for cancer: advancing diagnosis, prognosis, and treatment response—an NCI workshop reportJNCI Journal of the National Cancer Institute · Wed,
5Novel framework for the validation of intermediate clinical endpoints in oncology real-world dataJNCI Journal of the National Cancer Institute · Mon,

More from JNCI Journal of the National Cancer Institute

Effects of private health insurance coverage gains on colorectal cancer outcomes: a modeling studyMon,
Identification of prediagnostic proteomic biomarkers for colon and rectal cancer in 3 prospective cohortsMon,
Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN studyMon,
Colonoscopy screening outcomes in Lynch syndrome and differential colorectal cancer paths among MLH1 / MSH2 carriersMon,
Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumMon,